137
market here in Canada, it plans to capitalize on the larger German market and be one of the first movers there. The company has set up a new subsidiary called Maricann GmbH, and appointed an Advisory Board with considerable knowledge and experience in Germany (and globally) and are well connected with German healthcare and insurance industries. The large facility acquired in Dresden, Germany for €3.4 million is configured ideally for cultivation already. The depressed economy locally, plus tax credits make this a smart play in-country. All told, the facility will cost approximately six million euros after retrofitting is
complete, a bargain compared with their competitors, who are spending “north of $70 million for facilities with less than 1/3 the footprint” of Maricann’s location. Initial plans call for approximately 150,000 square feet of cultivation capacity with the facility. They anticipate receiving both a Narcotics Import and Wholesale license by the end of this month. It expected to receive GMP certification in February for its permit to export to Germany, however, as of today there has been no update on their progress in this regard. Keep an eye out for an update soon.
More recently Tetra Bio-Pharma Inc. (TSXV:TBP; OTC:TBPMF) announced that it will be seeking “CE Marking” for its RxPrinceps Inhalation Device, which used in conjunction with its RxPrinceps dry cannabis product (or any other), provides relief for cancer pain and other pain related ailments in measured consistent dosage. CE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA). The CE marking is also found on products sold outside the EEA that are manufactured in, or